Nature Cell Biology Retracted Osteosarcoma Study
The journal withdrew a 2020 paper on metastasis after finding recurring image anomalies and data irregularities.
Updated on Oct. 1, 2026 in Life Sciences
Editors at Nature Cell Biology have officially retracted an article regarding osteosarcoma metastasis, citing multiple instances of image similarity and underlying source data anomalies. The editorial board confirmed that the findings and conclusions of the 2020 study are no longer considered reliable.
Why it matters
The retraction underscores the rigorous scrutiny applied to experimental data in cancer research to ensure reproducibility and scientific integrity. It highlights the growing importance of image forensic analysis in validating high-stakes metastasis studies.
The retraction affects 14 specific figure references, including panels in figures 1, 3, and 6, alongside multiple extended data figures. These concerns regarding source data and image reuse were deemed unresolved by the editors after the authors' provided explanations proved unsatisfactory.
The players
Nature Cell Biology
A peer-reviewed scientific journal covering cell biology research with a focus on high-impact findings in cellular processes and disease mechanisms.
Jia Chen
An author of the original research article who has agreed with the formal retraction.
Song Gao
An author of the original research article who has agreed with the formal retraction.
Dan Liao
An author of the original research article who has formally expressed disagreement with the retraction decision.
Tiebang Kang
An author of the original research article who provided no clear statement regarding the retraction.
The details
The retracted study focused on the role of the Rab22a protein, a small GTPase protein involved in regulating membrane trafficking, in driving the spread of osteosarcoma. Editors identified significant anomalies by comparing experimental images for signs of unauthorized reuse across distinct conditions. While some authors pointed to shared control groups to explain the similarities, the editorial board determined these explanations failed to account for the breadth of the irregularities across the dataset.
Timeline
October 1, 2026: The formal retraction notice was published.
The Tech Race
This retraction reflects a broader trend toward intensified digital forensic auditing of peer-reviewed oncology literature. It follows industry-wide initiatives to identify image reuse and data fabrication in life sciences research.
This development invalidates prior conclusions regarding Rab22a that researchers and clinicians may have relied upon for understanding tumor progression. Future studies in the field will now require independent validation of these specific metastatic pathways.
The takeaway
The integrity of metastatic research depends on strict adherence to primary data transparency and verifiable experimental imaging. Researchers should monitor future literature reviews to see how the correction of these findings impacts established models of osteosarcoma progression.
Further reading
For more on how reproducibility issues are addressed in professional publishing, visit Life Sciences.
More information
View the formal Nature Cell Biology retraction notice for complete details on the affected figures.
Source note: This article includes information reported by Nature.
